- Zocilurtatug pelitecan (Zoci) positioned to become Zai Lab’s first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC and NEC by the end of 2026 ...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib)...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the 44th Annual J.P. Morgan Healthcare Conference on...
COBENFY is the first major advance in schizophrenia treatment in decades, offering a novel mechanism of action distinct from other therapies COBENFY has already been included...
- ZL-1503, a promising treatment for moderate-to-severe atopic dermatitis and other Type 2 helper T-cell (Th2)-driven diseases, strengthens Zai Lab’s growing global pipeline ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...
– Zocilurtatug pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) data presented at Triple Meeting in October continues to demonstrate first- and best-in-class potential, supporting the recent initiation...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2025: ...